sb 203580 has been researched along with alpha bitter acid in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (alpha bitter acid) | Trials (alpha bitter acid) | Recent Studies (post-2010) (alpha bitter acid) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 67 | 1 | 31 |
Protein | Taxonomy | sb 203580 (IC50) | alpha bitter acid (IC50) |
---|---|---|---|
Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 9.3 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Capasso, A; D'Acunto, CW; Festa, M; Masullo, M; Piacente, S; Pizza, C; Rossi, AG | 1 |
1 other study(ies) available for sb 203580 and alpha bitter acid
Article | Year |
---|---|
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Cyclohexenes; Cytochromes c; Dose-Response Relationship, Drug; Flavonoids; Glioblastoma; Humans; Imidazoles; Italy; Mitogen-Activated Protein Kinases; Molecular Structure; Poly(ADP-ribose) Polymerases; Propiophenones; Pyridines; Reactive Oxygen Species; Terpenes | 2011 |